United Kingdom (UK) There are many monoclonal antibodies for which the hybridoma cell line is unavailable. To complement our hybridoma sequencing service, we are also offering a de novo antibody protein sequencing service.
By combining mass-spectrometry with high-accuracy de novo peptide sequencing and assembly of overlapping peptides, the amino acid sequences of the variable domains are determined.
We guarantee to deliver a functional antibody sequence along with a comprehensive sequencing report with full sequence coverage. In combination with our transient expression service, we can sequence an antibody and deliver recombinant versions in as little as 9 weeks.
De novo sequencing workflow: The antibody is digested using multiple enzymes. On each digest LC-MS-MS is performed and peptides predicted de novo. Using proprietary software, overlapping peptides are assembled into a full coverage protein sequence.
For more information please contact us.
| Customer provides | Mass Spectrometric Sequencing | Antibody Expression | Timeline | Deliverables |
|---|---|---|---|---|
| Monoclonal antibody, >0.2 mg, 95% pure |
|
|
9 weeks |
|